THU0364 SYSTEMIC SCLEROSIS OVERLAP AND NON-OVERLAP SYNDROMES SHARE SIMILAR CLINICAL CHARACTERISTICS BUT DRAMATICALLY DIFFERENT TREATMENT.
Marc Scherlinger(Université de Strasbourg), Marie‐Elise Truchetet(Centre National de la Recherche Scientifique), Christophe Richez(Centre National de la Recherche Scientifique), Emmanuel Chatelus(Laboratoire National de Référence), Jean Sibilia(Immunologie, Immunopathologie et Chimie Thérapeutique), Jean-Christophe Lutz(Université de Strasbourg), J.E. Gottenberg(Inserm), T. Schaeverbeke(Université de Bordeaux)
Cited by 0
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
|New England Journal of Medicine|2018|501
Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review
|Seminars in Arthritis and Rheumatism|2007|456
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group
|Annals of the Rheumatic Diseases|2014|432